Anika Therapeutics Reports Officer Compensation Changes, Board Updates

TL;DR

**Anika Therapeutics just updated executive compensation and board structure, signaling potential leadership changes.**

AI Summary

Anika Therapeutics, Inc. (NASDAQ: ANIK) filed an 8-K on February 26, 2024, reporting events that occurred on February 24, 2024. The filing primarily concerns changes in compensatory arrangements for certain officers and the departure or election of directors or officers. The company, based in Bedford, Massachusetts, operates in the surgical and medical instruments and apparatus industry.

Why It Matters

This filing signals potential shifts in executive leadership and compensation strategies at Anika Therapeutics, which could influence future company performance and investor confidence.

Risk Assessment

Risk Level: low — The filing reports standard corporate governance changes without indicating immediate financial distress or major operational risks.

Key Players & Entities

• Anika Therapeutics, Inc. (company) — Registrant
• February 24, 2024 (date) — Date of earliest event reported
• February 26, 2024 (date) — Filing date
• Bedford, Massachusetts (company) — Principal executive offices location
• Delaware (company) — State of incorporation

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select M

Filing Documents

• f8k_022624.htm (8-K) — 18KB
• 0001171843-24-000972.txt ( ) — 184KB
• anik-20240224.xsd (EX-101.SCH) — 3KB
• anik-20240224_lab.xml (EX-101.LAB) — 33KB
• anik-20240224_pre.xml (EX-101.PRE) — 22KB
• f8k_022624_htm.xml (XML) — 3KB

02 Departure of Directors or Certain Officers;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 24, 2024, Jeffery S. Thompson notified Anika Therapeutics, Inc. (the "Company") of his intention to retire from the Board of Directors (the "Board") after 13 years of dedicated service at the end of his current term. Mr. Thompson's retirement will be effective as of the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Following Mr. Thompson's retirement, the Board will be comprised of seven directors, and two Class I directors will be elected at the Annual Meeting. Mr. Thompson's decision is not due to any disagreement with the Company with respect to any matter relating to the Company's operations, policies or practices. In connection with Mr. Thompson's planned retirement, John B. Henneman, III, an independent director of the Company's Board since 2020, has been appointed Chair of the Board, effective immediately.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anika Therapeutics, Inc. Date: February 26, 2024 By: /s/ Cheryl R. Blanchard Cheryl R. Blanchard President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR